Journal of the International Association of Providers of AIDS Care 2017, Vol. 16(3) 226–232
Guidelines
June 2017
HIV strategic information for impact
Practical Guidance for collaborative interventions
A série ‘Informes Orçamentais’ consiste na análise e simplificação de instrumentos públicos de planificação, orçamentação e políticas sociais em Moçambique para a melhor compreensão pública.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
3rd Edition – July 2017
www.msfaccess.org
These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... the effectiveness of medically important antimicrobials, particularly those antimicrobials judged to be critically important to human medicine and also help preserve the effectiveness of antimicrobials for veterinary medicine, in direct support of the WHO global action plan on antimicrobial resistance
more
Lancet Planet Health 2017 Published Online November 6, 2017 http://dx.doi.org/10.1016/S2542-5196(17)30141-9
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more